Alzheimer's Disease Organization Landscape
Overview
flowchart TD
companies_ad_landscape_ranking["AD Organization Landscape"]
style companies_ad_landscape_ranking fill:#4fc3f7,stroke:#333,color:#000
companies_ad_landsca_0["Major Pharmaceutical Companies"]
companies_ad_landscape_ranking -->|"includes"| companies_ad_landsca_0
style companies_ad_landsca_0 fill:#81c784,stroke:#333,color:#000
companies_ad_landsca_1["Big Pharma with approved AD therapies or late-s"]
companies_ad_landscape_ranking -->|"includes"| companies_ad_landsca_1
style companies_ad_landsca_1 fill:#ef5350,stroke:#333,color:#000
companies_ad_landsca_2["Specialty Pharma"]
companies_ad_landscape_ranking -->|"includes"| companies_ad_landsca_2
style companies_ad_landsca_2 fill:#ffd54f,stroke:#333,color:#000
companies_ad_landsca_3["Biotechnology Companies"]
companies_ad_landscape_ranking -->|"includes"| companies_ad_landsca_3
style companies_ad_landsca_3 fill:#ce93d8,stroke:#333,color:#000
companies_ad_landsca_4["Mid-Size Biotechs Phase 2-3"]
companies_ad_landscape_ranking -->|"includes"| companies_ad_landsca_4
style companies_ad_landsca_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ad_landsca_5["Emerging Biotechs Phase 1-2"]
companies_ad_landscape_ranking -->|"includes"| companies_ad_landsca_5
style companies_ad_landsca_5 fill:#81c784,stroke:#333,color:#000
...Alzheimer's Disease Organization Landscape
Overview
Mermaid diagram (expand to render)
This page provides a comprehensive overview of organizations involved in Alzheimer's disease research, drug development, and patient advocacy. It tracks the full ecosystem including pharmaceutical companies, biotechnology firms, nonprofits, patient advocacy groups, contract research organizations, and international programs.
Major Pharmaceutical Companies
Big Pharma (with approved AD therapies or late-stage programs)
| Company | AD Programs | Key Assets | Status |
|---------|-------------|------------|--------|
| [Eli Lilly](/companies/eli-lilly) | 4 | [Donanemab](/entities/donanemab), Remternetug, Solanezumab | Phase 3 |
| [Biogen](/companies/biogen) | 3 | Aduhelm, Leqembi (with Eisai) | Approved + Phase 3 |
| [Roche](/companies/roche) | 5 | Gantenerumab, Crenezumab | Phase 3 |
| [Eisai](/companies/eisai) | 2 | Leqembi | Approved |
| [AbbVie](/companies/abbvie) | 2 | ABBV-916 | Phase 1 |
| [Novartis](/companies/novartis) | 2 | Bilingual, CT1812 | Phase 1/2 |
| [Merck](/companies/merck) | 1 | MK-2514 (GLP-1) | Phase 1 |
| [Pfizer](/companies/pfizer) | 1 | PF-06423879 | Phase 1 |
Specialty Pharma
| Company | Focus | Key Assets |
|---------|-------|------------|
| [UCB Pharma](/companies/ucb-pharma) | [Tau](/proteins/tau), Synuclein | Bepranemab |
| [AstraZeneca](/companies/astrazeneca) | Neuroinflammation | AZD-5906 |
| [Takeda](/companies/takeda) | Amyloid | Multiple programs |
| [Janssen](/companies/janssen) | Tau, Neuroprotection | JNJ-63733657 |
| [Sanofi](/companies/sanofi) | Tau | SAR-422459 |
Biotechnology Companies
Mid-Size Biotechs (Phase 2-3)
| Company | Mechanism | Development Stage |
|---------|-----------|-------------------|
| [AC Immune](/companies/ac-immune) | Tau vaccine, α-syn vaccine | Phase 2/3 |
| [Prothena](/companies/prothena) | Prasinezumab (α-syn) | Phase 2 |
| [Denali Therapeutics](/companies/denali) | [LRRK2](/entities/lrrk2) inhibitor, ATN | Phase 2 |
| [Athira Pharma](/companies/athira-pharma) | HGF/MET activator | Phase 2/3 |
| [Cassava Sciences](/companies/cassava-sciences) | Filamin A modulator | Phase 3 |
| [Alzheon](/companies/alzheon) | Tau aggregation inhibitor | Phase 3 |
| [ProMIS Neurosciences](/companies/promis-neurosciences) | Aβ oligomer antibody | Phase 2 |
| [Acumen Pharmaceuticals](/companies/acumen-pharmaceuticals) | Aβ oligomer antibody | Phase 2 |
Emerging Biotechs (Phase 1-2)
| Company | Novel Approach | Technology |
|---------|---------------|------------|
| [Nodthera](/companies/nodthera) | [NLRP3](/entities/nlrp3-inflammasome) inhibitor | Small molecule |
| [Axsome Therapeutics](/companies/axsome-therapeutics) | Sigma-1 agonist | AXS-05, AXS-060 |
| [INmune Bio](/companies/inmune-bio) | TNF inhibitor | XPro1595 |
| [Alector](/companies/alector) | [TREM2](/proteins/trem2) activator | Latozinemab |
| [Lexeo Therapeutics](/companies/lexeo-therapeutics) | APOE4 gene therapy | LX1001 |
| [Life Biosciences](/companies/life-biosciences) | Tau aggregation inhibitor | Multiple |
Gene Therapy & Cell Therapy
| Company | Approach | Target |
|---------|----------|--------|
| [Voyager Therapeutics](/companies/voyager-therapeutics) | AAV gene therapy | Tau, Aβ |
| [Prevail Therapeutics](/companies/prevaint-therapeutics) | AAV-[GBA1](/entities/gba) | [Parkinson's](/diseases/parkinsons-disease) |
| [BlueRock Therapeutics](/companies/blue-rock-therapeutics) | Cell therapy | Dopamine [neurons](/entities/neurons) |
| [Sangamo Therapeutics](/companies/sangamo-therapeutics) | Zinc finger | Multiple |
| [uniQure](/companies/uniqure) | AAV gene therapy | [Huntingtin](/proteins/huntingtin) |
Non-Profit Organizations & Foundations
Research Funders
| Organization | Focus | Activities |
|--------------|-------|------------|
| [Alzheimer's Drug Discovery Foundation (ADDF)](/institutions/addf) | Drug discovery | Funding early-stage AD research |
| [Bill & Melinda Gates Foundation](/institutions/bill-melinda-gates-foundation) | Global health | Neurodegeneration research |
| [Chan Zuckerberg Initiative](/institutions/chan-zuckerberg-initiative) | Neurodegeneration challenge | Funding novel approaches |
| [BrightFocus Foundation](/organizations/brightfocus-foundation) | AD, glaucoma, macular degeneration | Research grants |
Patient Advocacy
| Organization | Region | Focus |
|--------------|-------|-------|
| [Alzheimer's Association](/institutions/alzheimers-association) | US | Patient support, research funding |
| [Alzheimer's Society](/institutions/alzheimers-society) | UK | Patient support, research |
| [Alzheimer's Foundation of America](/institutions/afi) | US | Patient care and support |
Contract Research Organizations (CROs)
| Organization | Services | AD Expertise |
|--------------|----------|-------------|
| [IQVIA](/companies/iqvia) | Full-service | Strong |
| [Catalent](/companies/catalent) | Manufacturing | Strong |
| [Charles River Laboratories](/companies/charles-river) | Preclinical | Strong |
| [Covance](/companies/covance) | Full-service | Strong |
| [Parexel](/companies/parexel) | Clinical trials | Strong |
| [Medpace](/companies/medpace) | Clinical trials | Moderate |
| [ICON PLC](/companies/icon-plc) | Clinical development | Strong |
International Programs
European Initiatives
| Country/Region | Program | Focus |
|----------------|---------|-------|
| EU | [ Innovative Health Initiative](https://www.ihi.europa.eu) | Public-private partnerships |
| UK | Dementia Research Institute | Basic research |
| Germany | DZNE (German Center for Neurodegenerative Diseases) | Translational research |
Asian Programs
Japan
- [Takeda](/companies/takeda)
- [Eisai](/companies/eisai)
- [Astellas](/companies/astellas)
- [Daiichi Sankyo](/companies/daiichi-sankyo)
Korea
- [Kolon Life Science](/companies/kolon-life-science)
- [Samsung Bioepis](/companies/samsung-bioepis)
- [Genexine](/companies/genexine)
China
- [WuXi Biologics](/companies/wuxi-biologics)
- [Innovent Biologics](/companies/innovent)
- [BeiGene](/companies/beigene)
Research Institutions
Academic Medical Centers
| Institution | AD Research Focus |
|-------------|------------------|
| Mayo Clinic | Tau pathology, biomarkers |
| UCLA Brain Research Institute | Amyloid, tau, clinical trials |
| Massachusetts General Hospital | Clinical trials, imaging |
| Banner Alzheimer's Institute | Prevention trials |
| UC San Diego | Stem cell research |
Government Agencies
| Agency | Role |
|--------|------|
| NIH/NIA | Research funding, clinical trials |
| FDA | Drug approval |
| CDC | Public health |
Therapeutic Target Landscape
| Target | Companies | Status |
|--------|-----------|--------|
| [Amyloid-beta](/proteins/amyloid-beta) | Eli Lilly, Biogen, Roche, Eisai | Approved/Phase 3 |
| Tau | Roche, Novartis, Athira, Alzheon | Phase 2/3 |
| [α-Synuclein](/proteins/alpha-synuclein) | Prothena, Roche | Phase 2 |
| Neuroinflammation | Nodthera, INmune Bio | Phase 2 |
| TREM2 | Alector | Phase 2 |
| Synaptic plasticity | Multiple | Early stage |
Pipeline Summary
See Also
- [AD Pipeline](/companies/ad-pipeline)
- [Company Rankings](/companies/rankings)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Therapeutic Mechanism Index](/companies/mechanism-index)
References
Unknown, ClinicalTrials.gov AD Pipeline (2024) (2024)
Unknown, Alzheimer's Association Facts and Figures (n.d.)
Unknown, ADDF Research Directory (n.d.)